期刊文献+

国产依布利特转复心房颤动/心房扑动的疗效及安全性研究 被引量:3

Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter
下载PDF
导出
摘要 目的:探讨静脉应用国产依布利特转复心房颤动(房颤)/心房扑动(房扑)的有效性和安全性。方法:筛选18~75岁,持续时间≤90 d(1 h~90 d),心室率≥60次/min的阵发性或持续性房颤/房扑患者共99例,随机分为依布利特组和普罗帕酮组各49和50例。依布利特组首剂1mg静注,如无效10 min后再给予1 mg。普罗帕酮组首剂70 mg静注,如无效10 min后再给予70mg。结果:两组均能有效降低房颤/房扑的心室率。转复率:依布利特组69.39%(34/49),普罗帕酮组44.00%(22/50),两组差异有统计学意义(P<0.05);转复时间:依布利特组显著短于普罗帕酮组(16.79±12.31)min对(36.92±11.38)min,P<0.01。不良反应:依布利特组最严重的不良反应为非持续性单形性室速,发生率6.12%(3/49),普罗帕酮组多为一过性低血压及长间歇,一例出现急性左心衰。结论:依布利特转复房颤/房扑的疗效高于普罗帕酮,转复时间短于普罗帕酮,不良反应发生率低,但须在严格监控下进行。 Objective: To investigate the efficacy and safety of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to sinus rhythm. Methods : Ninety-nine consecutive patients aged 18 -75 y with AF/AFL were included. The duration of arrhythmia was 〈90 d( 1 h -90 d) and ventricular rate was 〉 60 beats/min. Patients were assigned randomly into two groups: 49 patients in ibutilide group received ibutilide 1 mg, then repeated if AF/AFL was not converted after 10 min; 50 patients in propafenone group received propafenone 70 mg, then repeated if AF/AFL persisted after 10 min. Two drugs were diluted by 50 ml of 5% glucose and injected intravenously within 10 min. Results: Ventricular rates were decreased in both groups. AF/AFL were converted in 34 of 49 patients(69.4% ) in ibutilide group and in 22 of 50 patients(44.0% ) in propafenone group(P 〈 0.05 ). The converting time of ibutilide was significantly shorter than that of propafenone [ ( 16.79 ± 12.31 ) min vs (36.92 ± 11.38 ) min,P 〈0.01 ]. The most serious adverse effect of ibutilide was non-sustained monomorphic ventricular tachycardia(3/49,6. 12% ). Transient hypotension and heart pause were the main adverse events in patients who received propafenone, acute left heart failure occurred in one patient of propafenone group. Conclusions: Intravenous ibutilide is a safe and effective agent for cardioversion of recent-onset AF/ AFL. Furthermore, strict processing under electrocardio-monitoring is important.
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2013年第2期212-216,共5页 Journal of Zhejiang University(Medical Sciences)
关键词 抗心律失常药 治疗应用 普罗帕酮 治疗应用 心房颤动 药物疗法 心房扑动 药物疗法 输注 静脉内 治疗效果 Anti-arrhythmia agents/therapeutic use Propafenone/therapeutic use Atrial fibrillation/ drug therapy Atrial flutter/drug therapy Infusions, intravenous Treatment outcome
  • 相关文献

参考文献14

  • 1STAMBLER B S, WOOD M A, ELLENBOGEN K A. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation : electrophysiological deteminats of enhanced conversion efficacy [ J ]. Circulation, 2005,96 : 4298 -4306.
  • 2VOLGMAN A S, CARBERRY P A, STAMBLERB, et al. Conversion efficacy an safety of intravenous ibutilide compared with intravenous procainmide in patients with atrial flutter or fibrillation [ J ]. J Am Coil Cardio1,2008,31 : 1414-1419.
  • 3MILLER M R, MCNNAMARA R L, SEGA1 J B, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm : a meta-analysis of clinical trial [ J ]. J Fain Pract,2009,g9( 11 ) : 1033-1046.
  • 4CROPP J S, ANTAL E G, TALBERT R L, et al. Ibutilide: a new class antiarrhythmic agent [ J ]. Parmarcothrrapy,2010,17 : 1-9.
  • 5NACCARELLI G V, LEE KS, GIBSON J K, et al. Electrophysiology and pharmacology of ibutilide [ J ]. Am J Cardiol,2010,78 : 12-16.
  • 6GOLITSYN S R, STANGL K. Superiority of ibutilide (a new class m agent ) over DL-sotalol in converting atrial flutter and atrial fibrillation [ J ]. Heart,2009,79:568-575.
  • 7TAI C T, CHEN S A, FENG A N, et al.lectropharmalogic effects of class I and class antiarrhythmia drugs on typical atrial flutter [ J ]. Circulation,2006,97 : 1935-1945.
  • 8MILLER M R, MCNAMARA R L, SEGAL J B, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm : a meta-analysis of clinical trims [ J ]. J Faro Pract,2009,49 : 10033-1046.
  • 9VARRIALE P, SEDIGHI A. Acute management of atrial fibrihation and atrial flutter in the critical care unit : should it be ibutilide [ J ]. Ciin Cardliol, 2010,23(4): 265-268.
  • 10GOWDW R M, PUNUKOLLU G, KHAN L A, et al. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter impact of race on efficacy and safety [ J]. Am J Ther,2010, 10: 259-263.

同被引文献50

  • 1黄岸佳,韩群英.胺碘酮治疗急诊阵发性室上性心动过速疗效与安全性分析[J].中国实用内科杂志,2013,33(S1):122-123. 被引量:9
  • 2周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1397
  • 3Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Europace,2006,48:651-745.
  • 4Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.J Am Coll Cardiol,2011,57:101-198.
  • 5中国生物医学工程学会心律分会,中国医药生物技术协会心电学技术分会,中国医师协会心血管内科医师分会.伊布利特临床应用中国专家共识(2010).中国心脏起搏与心电生理杂志,2011,25:1-11.
  • 6Kannankeril PJ,Norris KJ,Carter S,et al.Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers.Heart Rhythm,2011,8:1530-1534.
  • 7Pastori D, Farcomeni A, Bueci T, et al. Digoxin treatment is associated with in- creased total and cardiovascular mortality in anticoagulated patients with atrial fi- brillation [ J ]. lnt J Cardio1,2014,180C : 1-5.
  • 8Turakhia MP, Santangeli P, Winkehnayer WC, et M. Increased mortality associat- ed with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study [ J ]. J Am Coll Cardiol,2014,64 ( 7 ) :660 -668.
  • 9January CT,Wann LS,Alpert JS,et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [ J]. Circulation, 2014,130 (23):2071-2104.
  • 10Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation [ J]. Can J Cardio1,2014,30 (10) : 1114-1130.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部